FDC Ltd.

381.75

4.9 (1.3%)growUp

As on February 3, 2026
SectorHealthcare
IndustryPharmaceuticals & Biotechnology
Basic IndustryPharmaceuticals
Market Cap6,224 Cr
P/E Ratio23.3
Dividend Yield1.31 %
Trendline Performance

Unlock_ipo_icon.webpUnlock Stock of the Month

T&C*

Company Information


Market Insights
Open392.6
High393
NSE SymbolFDC
Close381.75
Low378.6
BSE Symbol531599
Previous Years High/Low
1 Year High527.8
3 Year High658.85
5 Year High658.85
1 Year Low358.75
3 Year Low245.25
5 Year Low225

Technicals


IndicatorsValueSignal
5-DMA375.53Bullish
10-DMA373.84Bullish
20-DMA385.01Bearish
50-DMA403.4Bearish
100-DMA423.89Bearish
200-DMA444.13Bearish

Historical Performance


1 Year
-20.1%
3 Years
49.2%
5 Years
29.7%
10 Years
98.8%

Shareholding Pattern


Values Analysis


Loading chart...

Profit & Loss

Below figures are in Rs. Crores


ParticularsMar-2025Mar-2024Mar-2023Mar-2022Mar-2021
Net Sales21,08119,42917,83815,27913,332
Total Expenditure17,83316,04415,34212,7429,991
Other Income9071,016512761970
Operating Profit4,1554,4023,0083,2984,311
Interest4540413134
Depreciation537399389373378
Profit Before Tax3,5723,9622,5782,8943,877
Consolidated Net Profit2,6683,0511,9402,1643,013
Adjusted EPS1619121318
Compounded Sales Growth
10 Years:18.8
5 Years:9.4
3 Years:6.6
TTM:1.6
Compounded Profit Growth
10 Years:12.5
5 Years:2.1
3 Years:4.3
TTM:-2.6
Stock Price CAGR
10 Years:7.4
5 Years:4.6
3 Years:14.3
TTM:-19.9
Return on Equity
10 Years:9.5
5 Years:17.9
3 Years:11.7
last year:16.4

Quarterly Results

Below figures are in Rs. Crores


ParticularsSep-2024Dec-2024Mar-2025Jul-2025Sep-2025
Sales1,70,7541,35,9361,28,5521,22,1891,05,161
Expenses63,04256,55752,45745,45934,856
Operating Profit1,07,71279,37976,09676,73070,304
OPM %63%58%59%63%67%
Other Income33,91231,75927,33324,87918,947
Interest77,78058,58459,24862,13753,713
Depreciation2,3451,6811,3851,2771,221
Profit Before Tax61,49850,87342,79638,19534,318
Tax %25%25%26%29%35%
Net Profit46,14938,15131,85727,29622,446
EPS in Rs8369585042

Balance Sheet

Below figures are in Rs. Crores


ParticularsMar-2025Mar-2024Mar-2023Mar-2022Mar-2021
Share Capital163163166169169
Total Reserves22,64820,80919,65519,39917,172
Long-Term Borrowings---------------
Total Non-Current Liabilities8,1196,0424,6863,9122,996
Other Current Liabilities1,2461,015966864774
Short Term Borrowings---------------
Total Liabilities36,43333,16531,79630,37926,554
Capital Work in Progress1,3612,6091,9771,047192
Long Term Loans & Advances8,3326,0954,8744,2413,287
Currents Investments4,8474,5004,5735,0085,248
Short Term Loans and Advances2,4163,6534,9974,8044,504
Total Current Assets12,74013,67014,43114,18413,479
Total Assets36,43333,16531,79630,37926,554
Adjusted Book Value140129119116103
0%
Positive
(80 to 100)
Neutral
(60 to 79)
Negative
(0 to 59)
  • The stock has a moderate PE of 23.3, suggesting fair valuation relative to earnings.
  • Over the last three years, the stock delivered a moderate 3-year price CAGR of 13.6%, reflecting average market performance.
  • The stock carries a low beta of 0.6, suggesting lower volatility than the broader market.
  • In the last financial year, the company reported an EBITDA of ₹4155 million, reflecting positive operating performance.
  • In the previous financial year, the company generated revenue of ₹21081 million, indicating a large and established business.

Investment Calculator


Investment Amount:

Investment Amount: ₹ 1000000
Current Value: ₹ 801490.7
No. of Shares: 2100 (Approx)
Performance:-19.9%
P/L: ₹-198509.3
NIFTY Performance: 8.4%
1 day Top Gainers
SymbolChange%
WELSPUNLIV146.61(20%)
APARINDS9759(20%)
AARTIIND429.7(15%)
KPRMILL988.95(15%)
LTFOODS411.9(14%)
1 Day Top Losers
SymbolChange%
POLICYBZR1462.1(-7%)
VBL451.1(-3%)
RAINBOW1114.5(-3%)
CHENNPETRO840.9(-3%)
KANSAINER228.14(-3%)
OLAELEC31.03(-3%)
MEDANTA1113.2(-2%)
NSLNISP41.33(-2%)

Top Performing Stocks from the same sector


Biofil Chemicals & Pharmaceuticals Ltd.

38.4%

46.34

1 Month Performance

NGL Fine-Chem Ltd.

28.1%

1803.5

1 Month Performance

Mangalam Drugs And Organics Ltd.

25%

37.9

1 Month Performance

Ind-Swift Laboratories Ltd.

23.8%

113.37

1 Month Performance

Acutaas Chemicals Ltd.

12.6%

1969.7

1 Month Performance

Bliss GVS Pharma Ltd.

10.9%

180.52

1 Month Performance

Gland Pharma Ltd.

10.5%

1895.7

1 Month Performance

Rubicon Research Ltd.

9.1%

721.9

1 Month Performance

Get Your Portfolio Reviewed

Stock of the Month
Stock of the Month